[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Buchbinder D, Danielpour M, Yong WH, Salamon N, Lasky J: Treatment of atypical central neurocytoma in a child with high dose chemotherapy and autologous stem cell rescue. J Neurooncol; 2010 May;97(3):429-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of atypical central neurocytoma in a child with high dose chemotherapy and autologous stem cell rescue.
  • The authors describe a 9 month old female with recurrent atypical central neurocytoma and leptomeningeal spread treated with high dose chemotherapy, autologous stem cell rescue, and adjuvant therapy.
  • She had a complete response to therapy and was disease free at 4 years of age until a recurrence 6 months later.
  • The use of intensive chemotherapy followed by autologous stem cell rescue for atypical neurocytoma may be considered as an adjunct to surgical therapy in young patients with atypical neurocytoma not amenable to radiation therapy.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / surgery. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / surgery. Neurocytoma / drug therapy. Neurocytoma / surgery
  • [MeSH-minor] Female. Humans. Infant. Magnetic Resonance Imaging. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jan 1;88(1):169-74 [10618620.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1007-13 [19171716.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):663-73 [12548609.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4052-9 [14519626.001]
  • [Cites] Surg Neurol. 2003 Dec;60(6):560-5 [14670681.001]
  • [Cites] Pediatr Blood Cancer. 2004 Mar;42(3):261-7 [14752864.001]
  • [Cites] Arq Neuropsiquiatr. 2003 Dec;61(4):1030-4 [14762613.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):814-7 [14770439.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):377-84 [15015671.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1934-43 [15143087.001]
  • [Cites] J Neurooncol. 1990 Dec;9(3):231-8 [2086738.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):547-52 [9046315.001]
  • [Cites] J Neurooncol. 1997 Sep;34(3):279-83 [9258819.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):210-21 [9440745.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):197-204 [9457271.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2629-32 [15494975.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Nov;27(11):573-81 [16282886.001]
  • [Cites] Cancer Lett. 2006 Jan 18;231(2):262-9 [16399227.001]
  • [Cites] Neurosurgery. 2006 May;58(5):E990; discussion E990 [16639306.001]
  • [Cites] J Neurooncol. 2006 May;77(3):305-9 [16575540.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):211-6 [16552620.001]
  • [Cites] Neurosurg Rev. 2006 Oct;29(4):270-85; discussion 285 [16941163.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1528-37 [17077355.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1145-54 [17187939.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):354-63 [17452651.001]
  • [Cites] Pediatr Blood Cancer. 2008 May;50(5):970-5 [17941070.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):137-40 [18338396.001]
  • [Cites] Pediatr Blood Cancer. 2008 Dec;51(6):806-11 [18802947.001]
  • [Cites] Br J Neurosurg. 2002 Apr;16(2):126-32 [12046730.001]
  • (PMID = 19924515.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2858278
  •  go-up   go-down


2. Coelho Neto M, Ramina R, de Meneses MS, Arruda WO, Milano JB: Peritoneal dissemination from central neurocytoma: case report. Arq Neuropsiquiatr; 2003 Dec;61(4):1030-4
Genetic Alliance. consumer health - Central Neurocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal dissemination from central neurocytoma: case report.
  • OBJECTIVE: Central neurocytoma is a low grade tumor of neuroglial origin and a relatively new histological entity.
  • A case of central neurocytoma with peritoneal dissemination is presented.
  • CASE: A six years-old boy with recurrent neurocytoma of III ventricle and left thalamus showed fast growth of tumor rest and ascites three and a half years after subtotal removal of the lesion.
  • Chemotherapy was initiated immediately after diagnosis of peritoneal dissemination (etoposide, carboplatin, doxorubicin and cyclophosphamide).
  • The patient developed metabolic imbalance and respiratory failure due to rapid formation of ascitic fluid and died 3 days after the diagnosis of peritoneal dissemination was established.
  • CONCLUSION: Central neurocytoma is a low grade tumor with low values of the proliferative index in the majority of cases.
  • Evaluation of proliferative index may be a guideline parameter for planning adjuvant therapies after surgical treatment in selected cases.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Neurocytoma / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neoplasm, Residual. Peritoneum. Reoperation. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14762613.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Shravan Kumar C, Sharma DN, Sharma K, Haresh KP, Rath GK: Youngest case of third ventricular anaplastic neurocytoma. Indian J Med Paediatr Oncol; 2010 Apr;31(2):69-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Youngest case of third ventricular anaplastic neurocytoma.
  • The patient underwent gross tumor excision and histopathology confirmed anaplastic neurocytoma.
  • The postoperative MRI showed residual disease.
  • The patient treated with adjuvant radiotherapy and temozolamide chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jan 1;88(1):169-74 [10618620.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1111-20 [10964342.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):161-72 [11083081.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1252-60 [11688459.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1606-10 [10193953.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):551-6 [9143268.001]
  • [Cites] Pathology. 1998 Nov;30(4):355-9 [9839309.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):814-7 [14770439.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):197-204 [9457271.001]
  • (PMID = 21209769.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2970939
  • [Keywords] NOTNLM ; Anaplastic neurocytoma / MIB-1 labeling index / radiotherapy / synaptophysin / temozolamide
  •  go-up   go-down


Advertisement
4. Galanis E, Buckner JC: Chemotherapy of brain tumors. Curr Opin Neurol; 2000 Dec;13(6):619-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy of brain tumors.
  • This is a review of chemotherapy options for patients with brain tumors, both at the time of initial diagnosis and at recurrence.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neurocytoma / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11148660.001).
  • [ISSN] 1350-7540
  • [Journal-full-title] Current opinion in neurology
  • [ISO-abbreviation] Curr. Opin. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 46
  •  go-up   go-down


5. Brandes AA, Amistà P, Gardiman M, Volpin L, Danieli D, Guglielmi B, Carollo C, Pinna G, Turazzi S, Monfardini S: Chemotherapy in patients with recurrent and progressive central neurocytoma. Cancer; 2000 Jan 1;88(1):169-74
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in patients with recurrent and progressive central neurocytoma.
  • BACKGROUND: Recurrent central neurocytoma is very rare and to the authors' knowledge data regarding its response to chemotherapy currently are not available.
  • METHODS: Three patients with progressive neurocytoma received chemotherapy after their informed consent was obtained.
  • Disease recurred in two patients after surgery and radiotherapy and in one patient after surgery.
  • The treatment regimen was comprised of etoposide, 40 mg/m(2)/day, for 4 days; cisplatin, 25 mg/m(2)/day, for 4 days; and cyclophosphamide, 1,000 mg/m(2), on Day 4; this cycle was repeated every 4 weeks.
  • RESULTS: Stabilization of disease was observed in 2 patients and complete remission was observed in 1 patient; at last follow-up, these responses had been maintained for 15 months, 18 months, and 36 months, respectively.
  • CONCLUSIONS: In this small series, this therapeutic regimen led to long term disease reduction, and merits further study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Neurocytoma / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10618620.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Kim BJ, Kim SS, Kim YI, Paek SH, Lee YD, Suh-Kim H: Forskolin promotes astroglial differentiation of human central neurocytoma cells. Exp Mol Med; 2004 Feb 29;36(1):52-6
Genetic Alliance. consumer health - Central Neurocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Forskolin promotes astroglial differentiation of human central neurocytoma cells.
  • Human central neurocytoma is a kind of the brain tumors that are usually found in anterior part of the lateral ventricles.
  • In this study, we established conditions that allowed proliferation of neurocytoma cells culture and analyzed characteristics of neurocytoma cells in vitro.
  • RT-PCR analaysis showed that nestin was found in neurocytoma cells, indicating that the neurocytomas possess neural stem cell properties.
  • Interestingly, treatment of neurocytoma cells with forskolin increased expression of glial fibrillary acidic protein with a concomitant decrease in the nestin expression.
  • Forskolin also induced morphological changes of neurocytoma cells to adopt an astrocyte-like phenotype.
  • [MeSH-major] Astrocytes / physiology. Cell Differentiation / drug effects. Colforsin / pharmacology. Colforsin / therapeutic use. Neurocytoma / drug therapy
  • [MeSH-minor] Animals. Cell Proliferation. Cell Shape. Fibroblast Growth Factor 2 / pharmacology. Humans. Intermediate Filament Proteins / metabolism. Nerve Tissue Proteins / metabolism. Nestin. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15031671.001).
  • [ISSN] 1226-3613
  • [Journal-full-title] Experimental & molecular medicine
  • [ISO-abbreviation] Exp. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 103107-01-3 / Fibroblast Growth Factor 2; 1F7A44V6OU / Colforsin
  •  go-up   go-down


7. Rodríguez De Lope A, De La Lama A, López-Ariztegui N, Martínez R, Conde C, Fiaño C, Vázquez F: [Treatment of central neurocytoma. Experience at a single institution]. Neurocirugia (Astur); 2004 Apr;15(2):128-36; discussion 136-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of central neurocytoma. Experience at a single institution].
  • [Transliterated title] Tratamiento neurocitoma central. Experiencia en nuestro centro.
  • Central neurocytomas are classically considered as a rare, intraventricular benign tumours with neuronal differentiation derived from precursor cells of subventricular matrix.
  • Treatment of choice is complete surgical excision.
  • Adjuvant therapy is reserved for patients with residual or recurrent lesions including reoperation, radiotherapy or chemotherapy.
  • We review our experience with the treatment of this neoplasm.
  • Histopathological analysis confirmed central neurocytoma in all cases.
  • In this case adjuvant therapy with radiosurgery was given with important reduction in tumor size.
  • Complete surgical excision of central neurocytoma provides better local control and survival compared with other treatments.
  • Radiosurgery as adjuvant therapy in incomplete resections may eliminate the need of reoperation and avoid long-term side effects from conventional radiotherapy.
  • [MeSH-major] Brain Neoplasms / surgery. Neurocytoma / surgery

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15159790.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 56
  •  go-up   go-down


8. Jakacki RI, Hamilton M, Gilbertson RJ, Blaney SM, Tersak J, Krailo MD, Ingle AM, Voss SD, Dancey JE, Adamson PC: Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol; 2008 Oct 20;26(30):4921-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An oral erlotinib solution was administered during the dose-finding phase and a tablet formulation was subsequently studied at the maximum-tolerated dose (MTD).
  • At 110 mg/m(2)/d, two of four patients had dose-limiting toxicity (DLT) consisting of rash and hyperbilirubinemia, whereas one of six patients developed dose-limiting rash at 85 mg/m(2)/d.
  • One patient with a neurocytoma had stable disease for 19 months, two patients with neuroblastoma remained on study for 23 and 24 months, and one patient with myoepithelioma had a mixed response.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):2053-63 [10815932.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6841-5 [11156376.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3267-79 [11432895.001]
  • [Cites] Anticancer Drugs. 2004 Jun;15(5):503-12 [15166626.001]
  • [Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] Cancer Res. 1996 Sep 1;56(17):3898-901 [8752155.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4838-48 [9354447.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Feb 24;255(3):774-7 [10049786.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1786-92 [10430083.001]
  • [Cites] Pharmacol Ther. 1999 May-Jun;82(2-3):241-50 [10454201.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805 [15701870.001]
  • [Cites] Oncologist. 2005 Aug;10(7):508-17 [16079318.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5892-9 [16043829.001]
  • [Cites] BMC Cancer. 2005;5:131 [16219105.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] Drug Metab Dispos. 2006 Mar;34(3):420-6 [16381666.001]
  • [Cites] Clin Pharmacol Ther. 2006 Aug;80(2):136-45 [16890575.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5259-64 [17114659.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1228-38 [17283159.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3913-21 [17606725.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):998-1007 [10741727.001]
  • (PMID = 18794549.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / CA97452; United States / NCI NIH HHS / CA / P30 CA021765
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2652086
  •  go-up   go-down


9. von Koch CS, Schmidt MH, Uyehara-Lock JH, Berger MS, Chang SM: The role of PCV chemotherapy in the treatment of central neurocytoma: illustration of a case and review of the literature. Surg Neurol; 2003 Dec;60(6):560-5
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of PCV chemotherapy in the treatment of central neurocytoma: illustration of a case and review of the literature.
  • BACKGROUND: Most central neurocytomas follow a benign clinical course.
  • However, more aggressive variants have been described requiring additional surgical resection, radiation, or chemotherapy.
  • Chemotherapy has rarely been used as an adjuvant therapy for central neurocytomas.
  • METHODS: We report a case of a 20-year-old girl who underwent four subtotal resections, over the course of 3 years, for a large central neurocytoma that continued to progress.
  • To avoid radiation injury in a young patient, she was treated with six cycles of chemotherapy including procarbazine, CCNU, and vincristine.
  • Serial magnetic resonance imaging was used to follow treatment response.
  • RESULTS: Her tumor started to decrease in size after 2 cycles of chemotherapy and continued to shrink until it stabilized after 5 cycles of chemotherapy.
  • A small area of residual tumor with minimal enhancement persisted along the left lateral ventricle and remained stable for at least 16 months after the completion of chemotherapy.
  • CONCLUSIONS: To our knowledge, this is only the fourth report describing the use of chemotherapy for progression of central neurocytomas as a treatment alternative to radiation therapy.
  • The use of procarbazine, CCNU, and vincristine has not been previously described for the treatment of a central neurocytoma and presents an additional treatment option.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Lomustine / therapeutic use. Neurocytoma / drug therapy. Procarbazine / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14670681.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; PCV protocol
  • [Number-of-references] 20
  •  go-up   go-down


10. Swinson BM, Friedman WA, Yachnis AT: Pontine atypical neurocytoma: case report. Neurosurgery; 2006 May;58(5):E990; discussion E990

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pontine atypical neurocytoma: case report.
  • OBJECTIVE AND IMPORTANCE: Neurocytomas are typically located within the supratentorial ventricular system.
  • Extraventricular neurocytomas are very rare, and this is only the second reported case of a pontine neurocytoma.
  • We discuss the clinical presentation, histology, and treatment of these rare tumors.
  • CLINICAL PRESENTATION: A 58-year-old man presented with a 4-month history of headache and unilateral facial and distal extremity paresthesia.
  • INTERVENTION: MRI-guided stereotactic biopsy yielded a diagnosis of atypical neurocytoma.
  • Because of the location and malignant histological features of the tumor, the patient was initially treated with external beam radiation therapy.
  • The patient then underwent three rounds of temozolomide chemotherapy, during and after which his symptoms worsened.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Brain Stem Neoplasms / surgery. Neurocytoma / diagnosis. Neurocytoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639306.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Cemil B, Tun K, Guvenc Y, Ocakcioglu A, Ozen O: Extraventricular neurocytoma--report of a case. Neurol Neurochir Pol; 2009 Mar-Apr;43(2):191-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraventricular neurocytoma--report of a case.
  • Neurocytomas are typically located within the supratentorial ventricular system.
  • Extraventricular neurocytoma is a rare brain tumour that poses diagnostic difficulty.
  • We report a case of cerebral extraventricular neurocytoma.
  • The patient underwent surgical therapy, and a radical excision was performed.
  • The histological appearance and immuno-histochemical findings of the tumour are consistent with an extraventricular neurocytoma with anaplastic features.
  • Postoperatively, radiotherapy and chemotherapy may be used as adjuvant therapies.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neurocytoma / diagnosis
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Magnetic Resonance Imaging. Male. Radiotherapy, Adjuvant. Seizures / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19484697.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


12. Ruppert J: Central neurocytoma: a case study. J Neurosci Nurs; 2002 Aug;34(4):201-4
Genetic Alliance. consumer health - Central Neurocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central neurocytoma: a case study.
  • Central neurocytoma (CN) is a rare intraventricular brain tumor that affects young adults.
  • Gross total surgical resection is the treatment of choice for CN.
  • Other treatment modalities such as radiation therapy, radiosurgery, and chemotherapy may offer adjunctive or alternative treatment for residual or recurrent CN.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Cerebral Ventricle Neoplasms / nursing. Neurocytoma / diagnosis. Neurocytoma / nursing

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12197261.001).
  • [ISSN] 0888-0395
  • [Journal-full-title] The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses
  • [ISO-abbreviation] J Neurosci Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Rhiew RB, Manjila S, Lozen A, Guthikonda M, Sood S, Kupsky WJ: Leptomeningeal dissemination of a pediatric neoplasm with 1p19q deletion showing mixed immunohistochemical features of an oligodendroglioma and neurocytoma. Acta Neurochir (Wien); 2010 Aug;152(8):1425-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal dissemination of a pediatric neoplasm with 1p19q deletion showing mixed immunohistochemical features of an oligodendroglioma and neurocytoma.
  • The authors describe a case wherein a 1p19q deletion in a disseminated tumor with mixed immunohistochemical features of oligodendroglioma and neurocytoma was encountered and treated.
  • Stereotactic right frontal craniotomy was undertaken for obtaining definitive histological diagnosis.
  • The results revealed a neuroectodermal neoplasm with histologic and immunohistochemical features of oligodendroglioma and neurocytoma.
  • The patient was treated postoperatively with chemotherapy and radiation therapy.
  • He showed good clinical response and remains alive 16 months after diagnosis.
  • [MeSH-major] Brain Neoplasms / complications. Chromosomes, Human, Pair 1 / genetics. Gene Deletion. Meningeal Carcinomatosis / etiology. Mutation / genetics. Neurocytoma / complications. Oligodendroglioma / complications
  • [MeSH-minor] Child. DNA Mutational Analysis / methods. Diagnosis, Differential. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20446099.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


14. Psarros TG, Swift D, Mulne AF, Burns DK: Neurocytoma-like neoplasm of the thoracic spine in a 15-month-old child presenting with diffuse leptomeningeal dissemination and communicating hydrocephalus. Case report. J Neurosurg; 2005 Aug;103(2 Suppl):184-90
MedlinePlus Health Information. consumer health - Hydrocephalus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurocytoma-like neoplasm of the thoracic spine in a 15-month-old child presenting with diffuse leptomeningeal dissemination and communicating hydrocephalus. Case report.
  • This unusual mixed glioneuronal neoplasm of the spine resembling central neurocytoma is only the second reported example of a neoplasm of this type involving the spinal cord and is, seemingly, the first to present with diffuse leptomeningeal dissemination and communicating hydrocephalus.
  • The patient underwent cerebrospinal fluid shunt placement, thoracic laminectomy for tumor debulking and biopsy, chemotherapy, and radiation therapy to the neuraxis.
  • [MeSH-major] Arachnoid. Hydrocephalus / etiology. Neurocytoma / diagnosis. Pia Mater. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Cerebrospinal Fluid Shunts. Combined Modality Therapy. Humans. Immunohistochemistry. Infant. Laminectomy. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Reoperation. Thoracic Vertebrae. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hydrocephalus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16370289.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Schmidt MH, Gottfried ON, von Koch CS, Chang SM, McDermott MW: Central neurocytoma: a review. J Neurooncol; 2004 Feb;66(3):377-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central neurocytoma: a review.
  • Central neurocytomas are rare intraventricular neoplasms of the central nervous system, compromising 0.25-0.5% of brain tumors.
  • The diagnosis and management of these tumors remains controversial since most clinical series are small.
  • Typically, patients with central neurocytomas have a favorable prognosis, but in some cases the clinical course is more aggressive.
  • The most important therapeutic modality is surgery, and a safe maximal resection confers the best long-term outcome.
  • Re-operation for recurrence should be considered if the procedure can be safely performed.
  • Chemotherapy may be useful for recurrent central neurocytomas that cannot be resected and have been radiated, although long-term responses have not been reported for chemotherapy.
  • Overall, this paper reviews the findings of the larger studies and highlights some of the important case reports that contribute to the current management of central neurocytomas.
  • [MeSH-major] Brain Neoplasms / pathology. Neurocytoma / pathology

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 1990;79(5):473-9 [2109481.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):879-82 [11702880.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1606-10 [10193953.001]
  • [Cites] J Neurooncol. 1997 Sep;34(3):279-83 [9258819.001]
  • [Cites] Surg Neurol. 2001 Feb;55(2):74-8 [11301084.001]
  • [Cites] Pathol Oncol Res. 1999;5(2):155-9 [10393370.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Apr;70(4):489-93 [11254772.001]
  • [Cites] J Neurooncol. 1990 Dec;9(3):231-8 [2086738.001]
  • [Cites] Cancer. 1997 May 15;79(10):1995-2002 [9149028.001]
  • [Cites] Pathology. 1998 Nov;30(4):355-9 [9839309.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):249-54 [12675318.001]
  • [Cites] J Magn Reson Imaging. 2003 Feb;17(2):256-60 [12541233.001]
  • [Cites] J Neurosurg. 1992 Jan;76(1):32-7 [1727166.001]
  • [Cites] Br J Neurosurg. 1999 Oct;13(5):496-9 [10627783.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):506-9 [10470830.001]
  • [Cites] Br J Neurosurg. 2002 Apr;16(2):126-32 [12046730.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1365-7 [12015858.001]
  • [Cites] Lab Invest. 1991 Apr;64(4):585-91 [1901927.001]
  • [Cites] Mol Carcinog. 1993;8(2):74-80 [8397797.001]
  • [Cites] Neuroradiology. 1991;33(2):143-8 [2046899.001]
  • [Cites] Virchows Arch. 1997 Jan;430(1):47-51 [9037315.001]
  • [Cites] Neurosurgery. 2001 Feb;48(2):441-3 [11220392.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):547-52 [9046315.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):790-5 [9024717.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):297-306 [8293189.001]
  • [Cites] Neurology. 2002 Oct 22;59(8):1268-70 [12391364.001]
  • [Cites] Clin Neurol Neurosurg. 1995 Aug;97(3):219-28 [7586853.001]
  • [Cites] Neurosurgery. 2001 Jun;48(6):1231-7; discussion 1237-8 [11383724.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):329-33; discussion 333-4 [10690721.001]
  • [Cites] Surg Neurol. 1994 Oct;42(4):335-9 [7974132.001]
  • [Cites] Histopathology. 2000 Aug;37(2):160-5 [10931240.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):255-9 [12675319.001]
  • [Cites] J Neurooncol. 2003 May;62(3):269-73 [12777078.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1111-20 [10964342.001]
  • [Cites] Radiology. 1992 Mar;182(3):787-92 [1535895.001]
  • [Cites] J Neurosurg. 2002 Dec;97(6):1350-5 [12507133.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):551-6 [9143268.001]
  • [Cites] Acta Neuropathol. 1982;56(2):151-6 [7064664.001]
  • [Cites] Acta Radiol. 1993 Sep;34(5):520-6 [8369193.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):169-74 [10618620.001]
  • [Cites] J Neurosurg. 2000 Jul;93(1):77-81 [10883908.001]
  • [Cites] Cancer. 1993 Aug 15;72 (4):1350-5 [8339224.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):197-204 [9457271.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):327-30 [11213974.001]
  • (PMID = 15015671.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA09291
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


16. Amini E, Roffidal T, Lee A, Fuller GN, Mahajan A, Ketonen L, Kobrinsky N, Cairo MS, Wells RJ, Wolff JE: Central neurocytoma responsive to topotecan, ifosfamide, carboplatin. Pediatr Blood Cancer; 2008 Jul;51(1):137-40
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central neurocytoma responsive to topotecan, ifosfamide, carboplatin.
  • A 5-year-old male presented with spinal cord drop metastasis from a recurrent neurocytoma.
  • A literature review yielded 20 patients with central neurocytoma but no complete responses.
  • The complete response of central neurocytoma to chemotherapy only reported here should be helpful to those caring for patients with this rare tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neurocytoma / drug therapy
  • [MeSH-minor] Carboplatin. Child, Preschool. Disease-Free Survival. Humans. Ifosfamide. Magnetic Resonance Imaging. Male. Remission Induction. Topotecan

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18338396.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 18
  •  go-up   go-down


17. Chamberlain MC: Treatment of central neurocytomas. Expert Rev Neurother; 2002 Jul;2(4):464-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of central neurocytomas.
  • Central neurocytomas are uncommon tumors of the CNS, representing approximately 0.1-0.5% of all primary CNS tumors.
  • Rarely, central neurocytomas may present with a hemorrhage.
  • Central neurocytomas are intraventricular tumors with a predilection for arising in either the lateral or third ventricles.
  • Surgery provides definitive treatment, as little evidence exists as to response of these tumors to either radiotherapy or chemotherapy.
  • Uncommonly, anaplastic variants of central neurocytomas (malignant central neurocytomas) are encountered and are distinguished by frequent mitoses, necrosis and endothelial cell proliferation.
  • Following complete resection, central neurocytomas have a favorable prognosis usually obviating the need for either radiotherapy or chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19810943.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Anderson RC, Elder JB, Parsa AT, Issacson SR, Sisti MB: Radiosurgery for the treatment of recurrent central neurocytomas. Neurosurgery; 2001 Jun;48(6):1231-7; discussion 1237-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgery for the treatment of recurrent central neurocytomas.
  • OBJECTIVE: Central neurocytomas are benign neoplasms with neuronal differentiation typically located in the lateral ventricles of young adults.
  • Although the treatment of choice is complete surgical excision, patients may experience local recurrence.
  • Adjuvant therapy for patients with residual or recurrent tumor has included reoperation, radiotherapy, or chemotherapy.
  • Histopathological analysis confirmed central neurocytoma in all cases.
  • CONCLUSION: Radiosurgery with the gamma knife unit provides safe and effective adjuvant therapy after surgical resection of central neurocytomas.
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11383724.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Ogawa Y, Sugawara T, Seki H, Sakuma T: Central neurocytomas with MIB-1 labeling index over 10% showing rapid tumor growth and dissemination. J Neurooncol; 2006 Sep;79(2):211-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central neurocytomas with MIB-1 labeling index over 10% showing rapid tumor growth and dissemination.
  • OBJECTIVE AND IMPORTANCE: Central neurocytoma is recognized as a indolent intraventricular tumor arising from the ependyma around the foramen of Monro and anterior part of the lateral ventricles, and well demarcated from the brain parenchyma.
  • Surgical removal can be curative without postoperative therapy.
  • However, malignant central neurocytoma refractory to even aggressive treatment is known.
  • CLINICAL PRESENTATION: We report two cases of extraventricular central neurocytomas with significant vascular proliferation, mitoses, and MIB-1 labeling index of more than 10%.
  • INTERVENTION: Subtotal removal for the one patient and open biopsy for other followed by radiotherapy with chemotherapy were performed.
  • However, the disease progressed and dissemination occurred.
  • Both patients subsequently died 23 and 18 month after the histological diagnosis was established.
  • CONCLUSION: Extraventricular central neurocytoma may present with frequent vascular proliferation and high MIB-1 labeling index.
  • [MeSH-major] Brain Neoplasms / metabolism. Ki-67 Antigen / metabolism. Neurocytoma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Apr 1;85(7):1606-10 [10193953.001]
  • [Cites] Pathol Oncol Res. 1999;5(2):155-9 [10393370.001]
  • [Cites] J Neurooncol. 1997 Apr;32(2):103-9 [9120539.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Apr;20(4):724-7 [10319989.001]
  • [Cites] Cancer Metastasis Rev. 1991 Dec;10(4):321-33 [1786633.001]
  • [Cites] Cancer. 1997 May 15;79(10):1995-2002 [9149028.001]
  • [Cites] Cancer Surv. 1990;9(4):673-88 [2101728.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1252-60 [11688459.001]
  • [Cites] Lab Invest. 1991 Apr;64(4):585-91 [1901927.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):547-52 [9046315.001]
  • [Cites] Am J Surg Pathol. 1997 Feb;21(2):206-12 [9042288.001]
  • [Cites] Cancer Res. 1989 Apr 1;49(7):1797-801 [2924321.001]
  • [Cites] Hum Pathol. 1994 Aug;25(8):747-52 [8056420.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):551-6 [9143268.001]
  • [Cites] Acta Neuropathol. 1982;56(2):151-6 [7064664.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):169-74 [10618620.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):197-204 [9457271.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):161-72 [11083081.001]
  • [Cites] J Neurosurg. 1996 May;84(5):742-7 [8622146.001]
  • (PMID = 16552620.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


20. Leenstra JL, Rodriguez FJ, Frechette CM, Giannini C, Stafford SL, Pollock BE, Schild SE, Scheithauer BW, Jenkins RB, Buckner JC, Brown PD: Central neurocytoma: management recommendations based on a 35-year experience. Int J Radiat Oncol Biol Phys; 2007 Mar 15;67(4):1145-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central neurocytoma: management recommendations based on a 35-year experience.
  • PURPOSE: To examine the outcomes of patients with histologically confirmed central neurocytomas.
  • METHODS AND MATERIALS: The data from 45 patients with central neurocytomas diagnosed between 1971 and 2003 were retrospectively evaluated.
  • Various combinations of surgery, radiotherapy (RT), and chemotherapy had been used for treatment.
  • [MeSH-major] Brain Neoplasms / mortality. Neurocytoma / mortality
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Mitotic Index. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy Dosage. Retrospective Studies. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17187939.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Smets K, Salgado R, Simons PJ, De Clercq R, De Smedt K, Cras P: Central neurocytoma presenting with intraventricular hemorrhage: case report and review of literature. Acta Neurol Belg; 2005 Dec;105(4):218-25
Genetic Alliance. consumer health - Central Neurocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central neurocytoma presenting with intraventricular hemorrhage: case report and review of literature.
  • Computed Tomography (CT) scan and MRI without contrast showed a right ventricular hemorrhage surrounding a mass lesion.
  • Anatomopathological analysis revealed a central neurocytoma.
  • Central neurocytoma seldom present with hemorrhage.
  • We review 16 cases of neurocytoma with hemorrhage.
  • It is important to recognize central neurocytoma as a cause of intraventricular hemorrhage, especially in adolescents and young adults.
  • In some patients the clinical course is more aggressive and additional treatment such as radiotherapy, radiosurgery or chemotherapy is needed.
  • [MeSH-major] Cerebral Hemorrhage / etiology. Cerebral Ventricle Neoplasms / complications. Cerebral Ventricle Neoplasms / pathology. Neurocytoma / complications. Neurocytoma / pathology
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16482873.001).
  • [ISSN] 0300-9009
  • [Journal-full-title] Acta neurologica Belgica
  • [ISO-abbreviation] Acta Neurol Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


22. Engelhard HH, Stelea A, Cochran EJ: Oligodendroglioma: pathology and molecular biology. Surg Neurol; 2002 Aug;58(2):111-7; discussion 117
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chapters from standard textbooks were also used, and bibliographies were checked for additional key articles contributing to the understanding of the pathobiology of this disease.
  • RESULTS: On histologic examination, oligodendrogliomas must be differentiated from tumors including the fibrillary astrocytoma, clear cell ependymoma, central neurocytoma, and dysembryoplastic neuroepithelial tumor (DNT).
  • New molecular and genetic markers may aid in grading oligodendrogliomas and identifying patients with a better prognosis or response to chemotherapy.
  • The combination of allelic losses on chromosomes 1p and 19q has been statistically associated with a longer recurrence-free survival after chemotherapy.
  • CONCLUSIONS: A patient with an oligodendroglioma may at times still present a diagnostic challenge for the neuropathologist.
  • Yet making an accurate diagnosis is essential, since the clinical course and optimal therapeutic approach differs from that of other gliomas.


23. Kanamori M, Kumabe T, Watanabe M, Tominaga T: Anaplastic astrocytoma and anaplastic oligodendroglioma occurring 6 years after subtotal resection of a central neurocytoma. Case report. J Neurosurg; 2007 Jul;107(1):185-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma and anaplastic oligodendroglioma occurring 6 years after subtotal resection of a central neurocytoma. Case report.
  • The authors present the case of a 51-year-old man who presented with an anaplastic astrocytoma and anaplastic oligodendroglioma that developed 6 years after subtotal resection of a central neurocytoma in his right lateral ventricle.
  • He had received neither radiation therapy nor chemotherapy after the original resection.
  • These findings suggest that central neurocytoma or progenitor cells have the potential for oligodendrocytic and astrocytic transformation with different genetic aberrations.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neurocytoma / surgery. Oligodendroglioma / pathology
  • [MeSH-minor] Cell Transformation, Neoplastic. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Neurosurgical Procedures. Time Factors


24. Romano A, Chibbaro S, Makiese O, Marsella M, Mainini P, Benericetti E: Endoscopic removal of a central neurocytoma from the posterior third ventricle. J Clin Neurosci; 2009 Feb;16(2):312-6
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic removal of a central neurocytoma from the posterior third ventricle.
  • Central neurocytoma is a rare benign tumor that most commonly arises within the ventricular system of young adults.
  • These tumors are usually treated by a combination of either biopsy or open surgical resection, often followed by radiation (Gamma knife or Novalis) with or without chemotherapy.
  • A 37-year-old woman with a posterior third ventricle neurocytoma presented with acute signs of aqueductal stenosis.
  • The patient underwent endoscopic assisted gross total resection of the tumor with the aid of intraoperative laser followed by standard third ventriculostomy; no further treatment was required.
  • Thus, posterior third ventricle central neurocytomas are relatively benign tumors that can be successfully removed using a minimally invasive approach, thereby avoiding both the morbidity related to conventional open craniotomy and the potential toxicity of any adjuvant treatment.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Cerebral Ventricle Neoplasms / surgery. Endoscopy / methods. Neurocytoma / surgery. Third Ventricle / surgery

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19084413.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Technical Report
  • [Publication-country] Scotland
  •  go-up   go-down


25. Cai DX, Mafra M, Schmidt RE, Scheithauer BW, Park TS, Perry A: Medulloblastomas with extensive posttherapy neuronal maturation. Report of two cases. J Neurosurg; 2000 Aug;93(2):330-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors report on two patients with classic medulloblastoma, each of whom underwent extensive therapy-associated neuronal maturation.
  • Despite adjuvant chemotherapy, a 1.5-cm recurrent tumor developed 6 months later.
  • The specimen collected this time demonstrated classic medulloblastoma morphological characteristics.
  • The patient was subsequently treated with radiation therapy, which seemed to have an effect; however, the tumor eventually progressed and the patient died.
  • The second patient presented at 3 years of age with a midline medulloblastoma and was treated with subtotal resection, radiation therapy, and chemotherapy.
  • No adjuvant therapy was given and the patient is alive and well as of his last follow-up examination.
  • The smaller neuronal population resembled those of a central neurocytoma and medullocytoma/cerebellar neurocytoma.
  • Analogous to neuroblastoma, our cases suggest that adjuvant therapy can induce extensive or complete neuronal maturation in medulloblastoma.
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child, Preschool. Humans. Male. Neurons / cytology. Prognosis. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10930022.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


26. Warren K, Jakacki R, Widemann B, Aikin A, Libucha M, Packer R, Vezina G, Reaman G, Shaw D, Krailo M, Osborne C, Cehelsky J, Caldwell D, Stanwood J, Steinberg SM, Balis FM: Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. Cancer Chemother Pharmacol; 2006 Sep;58(3):343-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The combination of lobradimil and carboplatin was studied in pediatric patients with primary brain tumors in a phase II trial, the primary endpoints of which were to estimate the response rate and time to disease progression.
  • RESULTS: Forty-one patients, age 2-19 years, were enrolled; 38 patients, including 1 patient ultimately determined to have atypical neurocytoma, were evaluable for response.
  • No objective responses were observed in the brainstem glioma (n=12) and high-grade glioma (n = 9) cohorts, although two patients with high-grade glioma had prolonged disease stabilization (>6 months).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood-Brain Barrier / metabolism. Brain Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bradykinin / administration & dosage. Bradykinin / adverse effects. Bradykinin / analogs & derivatives. Bradykinin / therapeutic use. Carboplatin / administration & dosage. Carboplatin / adverse effects. Carboplatin / therapeutic use. Child. Child, Preschool. Cohort Studies. Drug Administration Schedule. Humans. Infusions, Intravenous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16408203.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 159768-75-9 / RMP 7; BG3F62OND5 / Carboplatin; S8TIM42R2W / Bradykinin
  •  go-up   go-down






Advertisement